Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Phase II Study
100%
Fibroblast Growth Factor Receptor 1 (FGFR1)
50%
Safety Profile
25%
Objective Response Rate
25%
Treatment-related Adverse Events
25%
Initial Part
25%
Long Follow-up
25%
North America
12%
Long-term Efficacy
12%
Medical Center
12%
Once-daily
12%
Europe
12%
Asia
12%
Cisplatin
12%
Adjuvant Chemotherapy
12%
One Dose
12%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
12%
Locally Advanced
12%
Hyponatremia
12%
Long-term Safety
12%
Treatment-related Mortality
12%
Neoadjuvant Chemotherapy
12%
Stomatitis
12%
Growth Factor Receptor Tyrosine Kinase
12%
Systemic Chemotherapy
12%
Progressive Disease
12%
Response Evaluation Criteria in Solid Tumors (RECIST)
12%
Safety Signal
12%
Advanced Urothelial Carcinoma
12%
Metastatic Urothelial Carcinoma
12%
Pharmacology, Toxicology and Pharmaceutical Science
Transitional Cell Carcinoma
100%
Erdafitinib
100%
Fibroblast Growth Factor Receptor
50%
Adverse Event
25%
Chemotherapy
25%
Solid Malignant Neoplasm
12%
Protein Tyrosine Kinase
12%
Cisplatin
12%
Hyponatremia
12%
Stomatitis
12%
Protein Tyrosine Kinase Inhibitor
12%
Diseases
12%
Medicine and Dentistry
Transitional Cell Carcinoma
100%
Adverse Event
25%
Protein Tyrosine Kinase
12%
Adjuvant Chemotherapy
12%
Oncology
12%
Cisplatin
12%
Stomatitis
12%
Neoadjuvant Chemotherapy
12%
Hyponatremia
12%
Tyrosine-Kinase Inhibitor
12%
Progressive Disease
12%
Response Evaluation Criteria in Solid Tumors
12%